Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 1/20 | 0.40 |
| ▸ | CMKLR1 | Q99788 | 4/20 | 0.39 |
| ▸ | MERTK | Q12866 | 1/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | SSTR2 | P30874 | 7/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.34 |
| ▸ | ITK | Q08881 | 1/20 | 0.33 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.33 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.33 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5219067 | 0.83 | CHEK2 (0.46) | CHEK2CMKLR1MERTKSSTR2BTK | |
| SCHEMBL5216967 | 0.76 | CHEK2 (0.46) | CHEK2CMKLR1CHEK1SSTR2 | |
| SCHEMBL7662650 | 0.74 | CHEK2 (0.42) | CHEK2CHEK1SSTR2AURKB | |
| SCHEMBL19297780 | 0.71 | CHEK2 (0.42) | CHEK2CHEK1AURKB | |
| SCHEMBL6945304 | 0.70 | CHEK2 (0.49) | CHEK2SSTR2AURKB | |
| SCHEMBL11449154 | 0.69 | LTA4H (0.50) | CHEK2 | |
| SCHEMBL5729040 | 0.68 | CHEK2 (0.48) | CHEK2MERTKCHEK1SSTR2 | |
| SCHEMBL6394083 | 0.67 | PTGS2 (0.47) | CHEK2MERTKCHEK1 | |
| SCHEMBL5729300 | 0.67 | PTGS2 (0.47) | CHEK2MERTKCHEK1 | |
| SCHEMBL5219061 | 0.66 | ESR1 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040034081-A9 | ESTROGEN RECEPTOR MODULATORS | CHIRON CORPORATION | 2004-02-19 | — | — | US | disclosed |
| US-20020111374-A1 | Estrogen receptor modulators | CHIRON CORPORATION | 2002-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034081-A9 | ESTROGEN RECEPTOR MODULATORS | ESR1, ESR2, GPER1 | CHEK2 1088/4885CMKLR1 1096/4885MERTK 1058/4885 |
| US-20020111374-A1 | Estrogen receptor modulators | ESR1, ESR2, GPER1 | CHEK2 1088/4885CMKLR1 1096/4885MERTK 1058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.